Cordovilla, R. (Rosa)

Filtering

2021 - 20232

Settings

Author search.filters.isAuthorOfPublication.280a5685-1bed-4cba-b180-6e3c8932161b

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Diagnosis and Treatment of Pleural Effusion. Recommendations of the Spanish Society of Pulmonology and Thoracic Surgery. Update 2022
    (2023) Cases, E. (Enrique); Valdés-Cuadrado, L. (Luis); Botana-Rial, M. (Maribel); Pérez-Pallarés, J. (javier); Porcel, J. M. (José Manuel); Cordovilla, R. (Rosa); Rodríguez-Pérez, M.C. (María C.); López-González, F. J. (Francisco Julián); Romero-Romero, B. (Beatriz); Villena-Garrido, V. (Victoria)
    Pleural effusion (PE) is a common yet complex disease that requires specialized, multidisciplinary management. Recent advances, novel diagnostic techniques, and innovative patient-centered therapeutic proposals have prompted an update of the current guidelines. This document provides recommendations and protocols based on a critical review of the literature on the epidemiology, etiology, diagnosis, prognosis, and new therapeutic options in PE, and addresses some cost-effectiveness issues related to the main types of PE.
  • Thumbnail Image
    Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial
    (2021) González-Ruiz, J.M. (José María); Campo, A. (Arantza); Villarón, E. (Eva); Andreu, E.J. (Enrique José); Torres, J.P. (Juan P.) de; Ocón-De-Miguel, M.M. (María M.); Alcaide, A.B. (Ana Belén); Cordovilla, R. (Rosa); Barrueco, M. (Miguel); Prosper-Cardoso, F. (Felipe); Nuñez-Cordoba, J.M. (Jorge M.); Zulueta, J. (Javier); Sanchez-Guijo, F.M. (Fermín M.); Pueyo, J. (Jesús)
    Rationale: Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases. Objectives: To evaluate the safety and feasibility of endobronchial administration of bone marrow autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF. Methods: A phase I multicentre clinical trial (ClinicalTrials.gov NCT01919827) with a single endobronchial administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first escalating-dose phase, three patients were included sequentially in three dose cohorts (10x10(6), 50x10(6) and 100x10(6) cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with pulmonary function testing, 6-min walk test and St George's Respiratory Questionnaire was done at 1, 2, 3, 6 and 12 months, and with computed tomography at 3, 6 and 12 months. Results: 21 bone marrow samples were obtained from 17 patients. Three patients were excluded from treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at 3 months and three (23%) at 12 months. Conclusions:..